A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Next Previous
Trial Profile

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 02 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 06 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 24 Sep 2015 Addition of toxicity study of the drug in primary endpoints and change of trial focus fro TU to TU & AR.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top